Trial Profile

Open-label, Phase 1 Study of S-488210/S-488211 to Evaluate the Safety and Tolerability in Patients With Unresectable Recurrent and/or Metastatic Solid Tumor

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs S 588210 (Primary)
Indications Bladder cancer; Head and neck cancer; Lung cancer; Mesothelioma; Oesophageal cancer; Pelvic cancer; Renal cancer; Solid tumours; Urethral cancer; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors Shionogi

Most Recent Events

25 Jan 2022 Status changed from recruiting to completed.
22 Jan 2021 Planned End Date changed from 31 Oct 2020 to 31 Oct 2021.
22 Jan 2021 Planned primary completion date changed from 31 Oct 2020 to 31 Oct 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com